These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

471 related articles for article (PubMed ID: 33404397)

  • 1. Hematologic parameters as biomarkers for antihistamine and omalizumab resistance in chronic spontaneous urticaria.
    Magen E; Waitman DA; Kahan NR
    Allergy Asthma Proc; 2021 Jan; 42(1):e17-e24. PubMed ID: 33404397
    [No Abstract]   [Full Text] [Related]  

  • 2. Interleukin-33, endothelin-1, and inflammatory parameters in chronic spontaneous urticaria.
    Kulumbegov B; Chikovani T; Gotua M; Kikodze N; Magen E
    Allergy Asthma Proc; 2023 Nov; 44(6):429-435. PubMed ID: 37919851
    [No Abstract]   [Full Text] [Related]  

  • 3. Response of peripheral blood basophils in subjects with chronic spontaneous urticaria during treatment with omalizumab.
    MacGlashan D; Saini S; Schroeder JT
    J Allergy Clin Immunol; 2021 Jun; 147(6):2295-2304.e12. PubMed ID: 33716077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors related to omalizumab resistance in chronic spontaneous urticaria.
    Magen E; Chikovani T; Waitman DA; Kahan NR
    Allergy Asthma Proc; 2019 Jul; 40(4):273-278. PubMed ID: 31262381
    [No Abstract]   [Full Text] [Related]  

  • 5. The efficacy of omalizumab treatment in chronic spontaneous urticaria is associated with basophil phenotypes.
    Johal KJ; Chichester KL; Oliver ET; Devine KC; Bieneman AP; Schroeder JT; MacGlashan DW; Saini SS
    J Allergy Clin Immunol; 2021 Jun; 147(6):2271-2280.e8. PubMed ID: 33713769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eosinopenia, in Chronic Spontaneous Urticaria, Is Associated with High Disease Activity, Autoimmunity, and Poor Response to Treatment.
    Kolkhir P; Church MK; Altrichter S; Skov PS; Hawro T; Frischbutter S; Metz M; Maurer M
    J Allergy Clin Immunol Pract; 2020 Jan; 8(1):318-325.e5. PubMed ID: 31472293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-TPO IgG/Total IgE Ratio: Biomarker for Omalizumab Response Prediction in Chronic Spontaneous Urticaria.
    Brás R; Esteves Caldeira L; Bernardino A; Costa C
    Int Arch Allergy Immunol; 2023; 184(9):866-869. PubMed ID: 37557083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In chronic spontaneous urticaria, increased Galectin-9 expression on basophils and eosinophils is linked to high disease activity, endotype-specific markers, and response to omalizumab treatment.
    Ji J; Tang M; Zhao Y; Zhang C; Shen Y; Zhou B; Liu C; Maurer M; Jiao Q
    Allergy; 2024 Sep; 79(9):2435-2447. PubMed ID: 39021347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are antihistamines still used during omalizumab treatment for chronic spontaneous urticaria?
    Melé-Ninot G; Serra-Baldrich E; Spertino J; Guilarte M; Ribó González P; Lleonart-Bellfill R; Figueras-Nart I; Bonfill-Ortí M; Depreux N; Sala-Cunill A; Bielsa-Marsol I; Baliu-Piqué C; Sanmartín-Novell V; Garcia-Navarro X; Expósito-Serrano V; Garnica-Velandia D; Diaz-Sarrió MC; Gómez-Armayones S; Gich Saladich I; Giménez-Arnau A
    Eur J Dermatol; 2022 Sep; 32(5):629-631. PubMed ID: 36468733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlations between disease activity, autoimmunity and biological parameters in patients with chronic spontaneous urticaria.
    de Montjoye L; Darrigade AS; Giménez-Arnau A; Herman A; Dumoutier L; Baeck M
    Eur Ann Allergy Clin Immunol; 2021 Mar; 53(2):55-66. PubMed ID: 31965967
    [No Abstract]   [Full Text] [Related]  

  • 11. Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study.
    Ghazanfar MN; Holm JG; Thomsen SF
    J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1761-1767. PubMed ID: 29729103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of drug therapies in antihistamine refractory chronic spontaneous urticaria: Real life data.
    Unsel M
    Asian Pac J Allergy Immunol; 2024 Jun; 42(2):138-146. PubMed ID: 33638629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of chronic inducible urticaria according to the guidelines: A prospective controlled study.
    Kocatürk E; Can PK; Akbas PE; Copur M; Degirmentepe EN; Kızıltac K; Singer R
    J Dermatol Sci; 2017 Jul; 87(1):60-69. PubMed ID: 28314658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antihistamine-resistant chronic spontaneous urticaria remains undertreated: 2-year data from the AWARE study.
    Maurer M; Costa C; Gimenez Arnau A; Guillet G; Labrador-Horrillo M; Lapeere H; Meshkova R; Savic S; Chapman-Rothe N
    Clin Exp Allergy; 2020 Oct; 50(10):1166-1175. PubMed ID: 32735720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atopy and Response to Omalizumab Treatment in Chronic Spontaneous Urticaria.
    Costa C; Esteves Caldeira L; Paulino M; Santos DF; Silva SL
    Int Arch Allergy Immunol; 2024; 185(3):260-266. PubMed ID: 38113870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective analysis omalizumab treatment patterns in patients with chronic spontaneous urticaria: a real-world study in Belgium.
    Lapeere H; Baeck M; Stockman A; Sabato V; Grosber M; Moutschen M; Lambert J; Vandebuerie L; de Montjoye L; Rabijns H; Allewaert K; Schrijvers R
    J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):127-134. PubMed ID: 31099916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences between adult and pediatric chronic spontaneous urticaria from a cohort of 751 patients: Clinical features, associated conditions and indicators of treatment response.
    Özçeker D; Can PK; Terzi Ö; Ornek SA; Değirmentepe EN; Kızıltac K; Sarac E; Kocatürk E
    Pediatr Allergy Immunol; 2023 Feb; 34(2):e13925. PubMed ID: 36825740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic Spontaneous Urticaria: An Update on the Evaluation and Management.
    Joshi SR; Anstey KM; Khan DA
    Immunol Allergy Clin North Am; 2024 Aug; 44(3):503-515. PubMed ID: 38937012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials.
    Maurer M; Casale TB; Saini SS; Ben-Shoshan M; Giménez-Arnau AM; Bernstein JA; Yagami A; Stjepanovic A; Radin A; Staudinger HW; Patel N; Amin N; Akinlade B; Fan C; Bauer D; Yancopoulos GD; Patel K; Mannent LP; Laws E
    J Allergy Clin Immunol; 2024 Jul; 154(1):184-194. PubMed ID: 38431226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Therapeutic Approaches and Targets for Treatment of Chronic Urticaria: New Insights and Promising Targets for a Challenging Disease.
    Martina E; Diotallevi F; Bianchelli T; Paolinelli M; Offidani A
    Curr Pharm Biotechnol; 2021; 22(1):32-45. PubMed ID: 32603278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.